MarketIntelligenceCenter.com's patented trade-picking algorithms have identified an attractive covered-call trade on Sanofi-Aventis (http://www.marketintelligencecenter.com/symbol/SNY"SNY). Look at the Sep. '15 $50.00 covered call for a net debit in ... Individual.com, 18 hours ago
Sanofi (SNY) Trading Near $50.52 Resistance Level - Individual.com, 1 day ago
Sanofi-Aventis Shares Sinking Lower, Down 2.6% - Individual.com, 2 days ago
Sanofi Announces Men With Advanced Prostate Cancer in England Will Continue to Have Access to Cabazitaxel..
/PRNewswire/ -- − Sanofi works with NHS England on interim agreement until NICE re-appraisal − Sanofi announced today that it has reached agreement with NHS England that cabazitaxel will once more be available on the NHS to clinically ...ADVFN India, 22 hours ago Sanofi prostate cancer drug to remain on CDF Pharmafile, 2 days ago Sanofi's Global Head for Prostate Drug, Zhen Su, Leaves Company Bloomberg, 6 days ago
German chancellor Dr. Angela Merkel met with Sanofi CEO Dr. Olivier Brandicourt, Boris Rhein, Hesse's Minister for Science and the Arts, leaders of the Fraunhofer Society and researchers from Sanofi to discuss the current status of antibiotics ...PharmaAsia, 6 hours ago New decision regarding MT Højgaard Group's activities at Thule EuroInvestor, 15 hours ago Sanofi hosts Angela Merkel at Frankfurt site European Pharmaceutical Manufacturer, 19 hours ago Sanofi Hosts German Chancellor Angela Merkel at Frankfurt Site EuroInvestor, 1 day ago
SAN CARLOS, Calif. , May 28, 2015 /PRNewswire/ --Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced the initiation of a multi-year Research Agreement with Sanofi Global R&D to ...BioSpace, 23 hours ago Rosa Co. Announces Multi-Year, World-Wide PhysioPD Research Agreement with Sanofi BioMedReports, 21 hours ago
Sanofi is spending $245 million to get hold of a voucher from the USA's Retrophin that can be used to speed up approval of a compound from its pipeline. Retrophin got hold of a Rare Pediatric Disease Priority Review Voucher when it bought ...Pharma Field, 1 day ago Retrophin bags $245M from Sanofi for priority review voucher Seeking Alpha, 1 day ago ViewPoints: Sanofi coy on how newly acquired priority review voucher will be used FirstWord Pharma, 1 day ago Sanofi to acquire FDA priority review voucher from Retrophin for $245 million FirstWord Pharma, 1 day ago
More from: Xconomy, Minyanville...and 35 other sources
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that NeuroVive Pharmaceutical Asia group has signed a collaboration agreement with Sanofi's local affiliate for the development and commercialization of CicloMulsion ...PharmaBiz, 1 day ago NeuroVive Asia, Sanofi to Jointly Develop and Market Ciclomulsion in South Korea PharmaAsia, 1 day ago NeuroVive Asia signs deal with Sanofi for CicloMulsion in South Korea Pharma Letter, 1 day ago NeuroVive Asia Inks Collaboration Deal With Sanofi For Growth Of CicloMulsion RTTNews.com, 3 days ago
Amgen, Inc. ( NYSE:AMGN ) and Sanofi SA ADR ( NYSE:SNY ) are all set to change the cholesterol drug market with their powerful new treatments that belong to a new class of drugs called PCSK9 protein inhibitors. The inhibitors work by targeting the ...Bidness Etc, 1 day ago Amgen vs. Sanofi: Cholesterol Blockbuster Battle Converter News, 1 day ago Amgen's Cholesterol Fighting Drug Receives EU Approval Guru Focus, 2 days ago
Employees lace up their running shoes to boost their daily physical activity levels and compete in the Global Corporate Challenge LAVAL, QC, May 27, 2015 /CNW Telbec/ - The Sanofi group in Canada is excited to announce that it will enter 57 teams ...Bloomberg, 1 day ago
More from: , Individual.com...and 1 other sources
Singapore: Sweden-based company NeuroVive Pharmaceutical's Asia arm has signed a collaboration agreement with Sanofi's affiliate for the development and commercialization of CicloMulsion in South Korea. Under the agreement NeuroVive Asia will get ...Bio Spectrum Asia, 2 days ago
NeuroVive Pharmaceutical Asia has entered a collaboration agreement with Sanofi's local subsidiary to develop and commercialise CicloMulsion in South Korea. NeuroVive's CicloMulsion, which is in a clinical development phase, is being developed to ...Pharmaceutical Technology, 3 days ago Sanofi to Co-Develop NeuroVive's CicloMulsion in South Korea Genetic Engineering News, 2 days ago
on your WebpageAdd Widget >Get your members hooked!